Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

The Vaccine Integrity Project will convene experts to assess the evidence on influenza, RSV, and Covid-19 to equip clinicians ...

A letter to the US public on the AMA website, signed by 75+ medical societies, stresses the vital importance of influenza, RSV, and COVID-19 vaccines.

SARS-CoV-2 infection in children and adolescents increases risk for cardiovascular disease, compared with uninfected individuals.

Merck & Co., Inc. (NYSE: MRK) is one of the. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

Go to source). In clinical trials, ENFLONSIA reduced serious RSV-related illnesses requiring medical attention by and lowered the risk of hospitalization due to RSV by more than 80%.

“Enflonsia provides an important new preventive option to help protect healthy and at-risk infants born during or entering their first RSV season,” Dr. Dean Y. Li, president of Merck Research ...

Enflonsia is an antibody designed to last in the body for about five months, which is long enough to protect an infant through a typical RSV season. The FDA decision for the product is based on ...